EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 5000
Summary
- Conditions
- Chronic Kidney Disease
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03594110
- Collaborators
- Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead)
- Eli Lilly and Company
- Investigators
- Not Provided
Get Well Soon